Regula’s ID Verification Software Is Now Compatible with Most Passport Readers on the Market
Leveraging its decades-long expertise in identity verification, Regula has made its advanced document verification software fully compatible with a wide range of third-party ID scanners and passport readers available on the market. Now, border control checkpoints, hotels, banks, medical organizations, and other institutions can take advantage of the most robust, forensic-level automated document verification and authentication regardless of the devices they are currently using.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250204069695/en/
Regula’s document verification software is fully compatible with a wide range of third-party ID scanners and passport readers on the market. (Graphic: Regula)
Regula’s ID verification software is an on-premises solution, which means it works offline and keeps sensitive ID data secure. It seamlessly integrates with leading passport readers and can be fully customized depending on the device model and its functional capabilities. This not only ensures quick migration to a robust identity verification (IDV) core solution, but also allows businesses and government agencies to maximize the potential of their existing hardware investments.
Forensic-level document verification
Regula’s ID verification software for document readers offers the most comprehensive set of ID authenticity checks. It automatically reads, analyzes, and cross-compares data from multiple sources, including RFID chips, machine-readable zones (MRZs), barcodes, and visual zones, to ensure they are consistent and not tampered with.
Regula’s software also supports authenticity checks in various illumination modes, such as white, ultraviolet (UV), infrared (IR), and coaxial lighting. Plus, the solution allows checking holograms and other optically variable devices and inks.
Global ID support
The software comes with the market’s most comprehensive identity document template database, which Regula owns and maintains. It currently contains over 14,800 ID templates from 251 countries and territories, and keeps growing. Also, the database enables the recognition of 138 languages and a great variety of scripts.
Optionally, the software can be integrated with the Regula Information Reference System, a unique digital collection of detailed images and descriptions of identity and vehicle documents, as well as banknotes and coins. Covering every country and territory in the world, the Regula Information Reference System contains over 337,000 high-resolution images of documents and their security features captured in different light sources. Thus, the system provides an indispensable and reliable reference to compare against, even for the rarest documents.
Effortless installation and flexible licensing
Designed with user convenience in mind, Regula’s ID verification software is a turnkey solution that can be installed in three clicks and requires no development time or tech-heavy resources. With extensive documentation and native support for all major frameworks and programming languages, the software integrates seamlessly into existing systems and workflows. The flexible licensing options fit almost any use case and cover various verification scenarios.
Streamlined document processing
Regula’s ID verification software takes document processing to the next level with its powerful and highly accurate Optical Character Recognition (OCR) technology. The software offers advanced capabilities such as support for parsing names, surnames, addresses, countries, and other key fields. It automatically divides text into separate fields—for instance, segmenting an address into postal code, state, and country—making the extracted data more organized and actionable. Additionally, the OCR module handles complex date formats and characters from different character sets within a single line, ensuring seamless data interpretation across diverse document types.
Future-ready solution
As identity verification standards and document formats continue to evolve, Regula stays at the cutting edge of this transformation. Not only is Regula’s IDV software constantly updated, but it proactively supports new identity document types, security features, and verification methods. For example, with its latest update, Regula ID verification software ensures full support of Digital Travel Credentials (DTCs), a new digital way of presenting and processing travel documents. With this approach, any passport reader will remain comprehensively equipped to perform the most innovative IDV checks.
“By ensuring compatibility with most passport readers on the market, we’re empowering organizations to leverage advanced ID verification software without the need for new hardware investments and drastic changes. Regula’s software offers forensic-level precision, customization and flexibility, as well as compliance with the highest security standards, setting a new benchmark for document authentication,” says Ihar Kliashchou, Chief Technology Officer at Regula.
To learn more about the features and capabilities of Regula’s ID verification software for passport readers, please visit the official website.
About Regula
Regula is a global developer of forensic devices and identity verification solutions. With our 30+ years of experience in forensic research and the most comprehensive library of document templates in the world, we create breakthrough technologies for document and biometric verification. Our hardware and software solutions allow over 1,000 organizations and 80 border control authorities globally to provide top-notch client service without compromising safety, security, or speed. Regula has been repeatedly named a Representative Vendor in the Gartner® Market Guide for Identity Verification.
Learn more at www.regulaforensics.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250204069695/en/
Contacts
Kristina – ks@regulaforensics.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press Release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press Release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press Release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press Release
Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity. Pimicotinib, a colony stimulating factor-1 receptor (CSF-1R) inhibitor developed by Abbisko Therapeutics Co., Ltd., Shanghai, China, is the first Chemical Drug Class 1 approved in China for the treatment of TGCT. “We are continuing to deliver on our commitment to improving the lives of patients with rare tumors with this first-in-the-world regulatory approval of pimicotinib,” said Danny Bar-Zohar, CEO Healthcare and Member of the Executive Board of Merck. “This approval is a significant step forward in further strengthening our leadership in rare tumors, while offering patients the opportunity to change the course of
Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press Release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom